Full text is available at the source.
Abstract
The impact of tirzepatide and dulaglutide on major adverse cardiovascular events (MACE) and heart failure outcomes is uncertain.
- The effects of tirzepatide on cardiovascular events and heart failure outcomes have not been established.
- Similarly, dulaglutide's influence on major adverse cardiovascular events is unclear.
- The relationship between heart failure status and the outcomes of these treatments remains to be determined.
Simplified